ALNY vs. VRTX: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALNY and VRTX, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
VRTX stands out with 111.79 billion USD in market value—about 2.93× ALNY’s market cap of 38.15 billion USD.
VRTX carries a higher beta at 0.51, indicating it’s more sensitive to market moves, while ALNY remains steadier at 0.17.
| Symbol | ALNY | VRTX |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | Vertex Pharmaceuticals Incorporated |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. | Dr. Reshma Kewalramani FASN, M.D. |
| Price | 292.58 USD | 435.32 USD |
| Market Cap | 38.15 billion USD | 111.79 billion USD |
| Beta | 0.17 | 0.51 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | June 1, 2004 | July 24, 1991 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALNY and VRTX over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALNY and VRTX based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- Neither ALNY nor VRTX turned a profit—both carry negative P/E ratios of -140.68 and -113.09, underscoring continued losses that pressure their valuations.
- Analysts assign negative forward PEG ratios to both ALNY (-38.16) and VRTX (-9.08), suggesting expectation of shrinking or negative earnings in the upcoming period—a worrying sign for their profit outlook.
- ALNY and VRTX both consumed more free cash flow than they generated last year—P/FCF of -506.05 and -88.86, respectively—highlighting persistent liquidity pressure.
| Symbol | ALNY | VRTX |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -140.68 | -113.09 |
| Forward PEG Ratio (TTM) | -38.16 | -9.08 |
| Price-to-Sales Ratio (P/S, TTM) | 16.25 | 10.07 |
| Price-to-Book Ratio (P/B, TTM) | 328.68 | 6.78 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -506.05 | -88.86 |
| EV-to-EBITDA (TTM) | -251.73 | -1425.47 |
| EV-to-Sales (TTM) | 16.37 | 9.80 |
| EV-to-Free Cash Flow (TTM) | -509.80 | -86.46 |
Dividend Comparison
Neither ALNY nor VRTX currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
| Symbol | ALNY | VRTX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALNY and VRTX, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ALNY is heavily leveraged (debt-to-equity ratio 11.28), which can boost returns but raises risk if borrowing costs climb, while VRTX at 0.10 keeps leverage at a more moderate level.
- Both ALNY and VRTX report negative interest coverage ratios (-0.79, -32.00), meaning EBIT itself is negative—neither can cover interest, a critical solvency warning.
| Symbol | ALNY | VRTX |
|---|---|---|
| Current Ratio (TTM) | 3.04 | 2.65 |
| Quick Ratio (TTM) | 2.98 | 2.29 |
| Debt-to-Equity Ratio (TTM) | 11.28 | 0.10 |
| Debt-to-Assets Ratio (TTM) | 0.31 | 0.07 |
| Interest Coverage Ratio (TTM) | -0.79 | -32.00 |